| Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis S Crisafulli, J Sultana, A Fontana, F Salvo, S Messina, G Trifirò Orphanet journal of rare diseases 15, 1-20, 2020 | 273 | 2020 |
| The economic burden of preventable adverse drug reactions: a systematic review of observational studies D Formica, J Sultana, PM Cutroneo, S Lucchesi, R Angelica, S Crisafulli, ... Expert opinion on drug safety 17 (7), 681-695, 2018 | 184 | 2018 |
| Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines J Sultana, PM Cutroneo, S Crisafulli, G Puglisi, G Caramori, G Trifirò Drug safety 43, 691-698, 2020 | 177 | 2020 |
| Challenges for drug repurposing in the COVID-19 pandemic era J Sultana, S Crisafulli, F Gabbay, E Lynn, S Shakir, G Trifirò Frontiers in pharmacology 11, 588654, 2020 | 139 | 2020 |
| COVID-19 vaccination in pregnancy, paediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current … N Luxi, A Giovanazzi, A Capuano, S Crisafulli, PM Cutroneo, MP Fantini, ... Drug safety 44 (12), 1247-1269, 2021 | 117 | 2021 |
| Potential role of anti-interleukin (IL)-6 drugs in the treatment of COVID-19: rationale, clinical evidence and risks S Crisafulli, V Isgrò, L La Corte, F Atzeni, G Trifiro BioDrugs 34 (4), 415-422, 2020 | 72 | 2020 |
| Pharmacokinetics of new oral anticoagulants: implications for use in routine care Y Ingrasciotta, S Crisafulli, V Pizzimenti, I Marciano, A Mancuso, G Ando, ... Expert opinion on drug metabolism & toxicology 14 (10), 1057-1069, 2018 | 62 | 2018 |
| Global epidemiology of acromegaly: a systematic review and meta-analysis S Crisafulli, N Luxi, J Sultana, A Fontana, F Spagnolo, G Giuffrida, ... European journal of endocrinology 185 (2), 251-263, 2021 | 53 | 2021 |
| Renin–angiotensin–aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian cohort study of 43,000 patients G Trifirò, M Massari, R Da Cas, F Menniti Ippolito, J Sultana, S Crisafulli, ... Drug Safety 43, 1297-1308, 2020 | 53 | 2020 |
| Kidney disease in diabetic patients: from pathophysiology to pharmacological aspects with a focus on therapeutic inertia G Gembillo, Y Ingrasciotta, S Crisafulli, N Luxi, R Siligato, D Santoro, ... International journal of molecular sciences 22 (9), 4824, 2021 | 51 | 2021 |
| A new era of pharmacovigilance: Future challenges and opportunities G Trifirò, S Crisafulli Frontiers in Drug Safety and Regulation 2, 1, 2022 | 32 | 2022 |
| Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study S Crisafulli, J Sultana, Y Ingrasciotta, A Addis, P Cananzi, L Cavagna, ... Expert Opinion on Drug Safety 18 (6), 497-509, 2019 | 29 | 2019 |
| Should patients receiving ACE inhibitors or angiotensin receptor blockers be switched to other antihypertensive drugs to prevent or improve prognosis of novel coronavirus … G Trifiro, S Crisafulli, G Ando, G Racagni, F Drago Drug Safety 43, 507-509, 2020 | 25 | 2020 |
| COVID-19 patient management in outpatient setting: a population-based study from Southern Italy S Crisafulli, V Ientile, L L’Abbate, A Fontana, C Linguiti, S Manna, ... Journal of clinical medicine 11 (1), 51, 2021 | 22 | 2021 |
| Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic … S Spila Alegiani, S Crisafulli, P Giorgi Rossi, P Mancuso, C Salvarani, ... Rheumatology 60 (SI), SI25-SI36, 2021 | 16 | 2021 |
| Incidence of skin cancer in patients with chronic inflammatory cutaneous diseases on targeted therapies: a systematic review and meta-analysis of observational studies S Crisafulli, L Bertino, A Fontana, F Calapai, Y Ingrasciotta, M Berretta, ... Frontiers in Oncology 11, 687432, 2021 | 14 | 2021 |
| Digital therapeutics in perspective: from regulatory challenges to post-marketing surveillance S Crisafulli, E Santoro, G Recchia, G Trifirò Frontiers in Drug Safety and Regulation 2, 900946, 2022 | 12 | 2022 |
| ITA-COVID-19: RAAS Inhibitor Group. Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian cohort … G Trifirò, M Massari, R Da Cas, FM Ippolito, J Sultana, S Crisafulli, ... Drug Saf 43 (12), 1297-1308, 2020 | 12 | 2020 |
| Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials S Crisafulli, N Luxi, R Coppini, A Capuano, C Scavone, A Zinzi, S Vecchi, ... BMC Family Practice 22, 1-11, 2021 | 10 | 2021 |
| Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy SS Alegiani, S Crisafulli, PG Rossi, P Mancuso, C Salvarani, F Atzeni, ... Rheumatology (Oxford) 60, SI25-36, 2021 | 10 | 2021 |
